Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GUARD Trial (Part 1)
NCT04136366Phase 3Completed
- Sponsor
- Aldeyra Therapeutics
- Start
- Nov 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ADX-2191 in Proliferative Vitreoretinopathy (PVR), sponsored by Aldeyra Therapeutics. Started Nov 2019; status: completed.
02
Drugs
ADX-2191
03
Conditions
Proliferative Vitreoretinopathy (PVR)
Beyond the preview
Go deeper on NCT04136366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04136366.